NASDAQ$CHRS
Coherus Biosciences Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Coherus reported financial results for the second quarter of 2024
Coherus BioSciences reported net revenue of $65.0 million for Q2 2024, including $50.9 million from UDENYCA, $3.8 million from LOQTORZI, $3.8 million from YUSIMRY, and $6.5 million from other revenue. The company's net loss for the quarter was $12.9 million, or $(0.11) per share.
- Net revenue for Q2 2024 was $65.0 million.
- UDENYCA net product sales were $50.9 million in Q2 2024, a 60% increase compared to Q2 2023.
- LOQTORZI net sales in Q2 2024 were $3.8 million, with new patient uptake primarily in relapsed locally advanced and 1L metastatic disease.
- An IND application for CHS-1000 was filed with the FDA in Q2 2024 and received clearance.
Headline financials
Revenue & EPS history
Coherus · Revenue · Quarterly
$65M
Forward guidance
Coherus projects combined R&D and SG&A expenses for 2024 to be in the range of $250 to $265 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
+0.3%
Avg return
Earnings day
-2.2%
Avg return
5 days after
+0.4%
Avg return
30 days after
53%
23 / 43 earnings
Positive
+28.8%
Q4 2017
Best reaction
-31.6%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.9% | -10.3% | — | |
| Q4 2025 | +1.6% | -15.5% | -14.5% | |
| Q3 2025 | -9.6% | -8.7% | -19.5% | |
| Q1 2025 | -18.7% | -25.4% | -22.5% | |
| Q4 2024 | +1.0% | -11.5% | -28.7% | |
| Q3 2024 | +12.2% | +6.6% | +132.6% | |
| Q2 2024 | +15.3% | +16.1% | +0.0% | |
| Q1 2024 | -14.8% | -6.7% | -24.2% | |
| Q4 2023 | -3.1% | -0.9% | -0.4% | |
| Q3 2023 | -31.6% | -56.0% | -36.6% | |
| Q2 2023 | +13.8% | +11.8% | +21.4% | |
| Q1 2023 | -19.9% | -33.6% | -27.1% | |
| Q4 2022 | +3.4% | -14.0% | +8.8% | |
| Q3 2022 | -10.4% | -0.4% | -12.7% | |
| Q2 2022 | +17.6% | +9.9% | +1.4% | |
| Q1 2022 | -13.3% | -12.3% | -22.1% | |
| Q4 2021 | -6.5% | -15.6% | +1.0% | |
| Q3 2021 | +4.9% | +4.5% | +1.9% | |
| Q2 2021 | +1.8% | +3.2% | +22.8% | |
| Q1 2021 | -1.6% | -3.2% | -8.8% | |
| Q4 2020 | -6.1% | -1.4% | -10.5% | |
| Q3 2020 | -7.6% | +2.3% | +4.9% | |
| Q2 2020 | +8.0% | +3.2% | +1.4% | |
| Q1 2020 | +6.9% | +4.9% | +16.2% | |
| Q4 2019 | -5.1% | -4.0% | -20.2% | |
| Q3 2019 | +16.4% | +15.1% | +11.1% | |
| Q2 2019 | +19.0% | +15.2% | +31.9% | |
| Q1 2019 | +8.4% | +4.7% | +11.1% | |
| Q4 2018 | +2.4% | +2.6% | -2.8% | |
| Q3 2018 | -19.4% | -10.7% | -16.3% | |
| Q2 2018 | +2.5% | +2.5% | +2.7% | |
| Q1 2018 | +5.8% | +4.5% | +1.8% | |
| Q4 2017 | +28.8% | +35.3% | +23.9% | |
| Q3 2017 | -6.9% | -15.9% | -29.7% | |
| Q2 2017 | +6.3% | -8.3% | +13.4% | |
| Q1 2017 | -1.5% | +13.2% | +4.6% | |
| Q4 2016 | -5.4% | -0.9% | -19.6% | |
| Q3 2016 | +15.7% | +16.1% | +16.6% | |
| Q2 2016 | -3.3% | -1.8% | +1.8% | |
| Q1 2016 | -6.3% | — | — | |
| Q4 2015 | +4.1% | — | — | |
| Q3 2015 | +0.5% | — | — | |
| Q3 2014 | -3.5% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro